Literature summary for 3.1.4.35 extracted from

Tamimi, N.A.; Mincik, I.; Haughie, S.; Lamb, J.; Crossland, A.; Ellis, P.
A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia (2010), BJU Int., 106, 674-680.

Search for more literature for 3.1.4.35

Inhibitors

Inhibitors	Comment	Organism	Structure
UK-369,003	i.e. 1-[6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridyl sulfonyl]-4-ethylpiperazine benzenesulfonate, a potent selective inhibitor of cGMP-specific PDE5 with more than 80fold selectivity for PDE5 over PDE6, more than 3000fold selectivity over PDEs 1-4 and 10, and more than 10000fold selectivity over PDE11	Homo sapiens

Natural Substrates/ Products (Substrates)

Natural Substrates	Organism	Comment (Nat. Sub.)	Natural Products	Comment (Nat. Pro.)	Rev.	Reac.
3',5'-cGMP + H2O	Homo sapiens	PDE5 is cGMP-specific	5'-GMP	-	?

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining

Substrates and Products (Substrate)

Substrates	Comment Substrates	Organism	Products	Comment (Products)	Rev.	Reac.
3',5'-cGMP + H2O	PDE5 is cGMP-specific	Homo sapiens	5'-GMP	-	?

Synonyms

Synonyms	Comment	Organism
PDE5	-	Homo sapiens
phosphodiesterase type 5	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)